
Planning, not panic, as BIO weighs in on US vaccination woes
At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.
Newsletters and Deep Dive digital magazine
At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.
Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.
People in England and Wales with severe skin disease GPP will soon be able to access a new therapy currently denied to patients in Scotland.
RFK Jr's interference in the ACIP is putting patients at risk, claim the 17 members of the panel abruptly fired last week.
Editor's Picks
Newsletters and Deep Dive
digital magazine